Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system
Abstract
BACKGROUND: An increase in urinary albumin excretion (UAE) represents an early predictor of glomerular damage in diabetes mellitus (DM) and a risk factor for cardiovascular complications in hypertension. Vasopressin is elevated in DM and in some forms of hypertension. Previous studies in rats suggested that this hormone could play a role in the albuminuria observed in chronic renal failure or diabetic nephropathy, but no information is available concerning the mechanism of these effects and the possible influence of vasopressin on UAE in the healthy kidney. The present study was thus designed to evaluate whether vasopressin influences UAE in normal rats and humans, whether this effect is V(2)-receptor-dependent, and whether it is mediated by the renin-angiotensin system. METHODS: UAE was measured in normal Wistar rats and healthy humans, or in subjects with various forms of diabetes insipidus (DI), before and after acute or chronic infusion of the vasopressin V(2) receptor agonist dDAVP. Chronic dDAVP administration was also performed in normal Wistar rats previously submitted to either chronic angiotensin-converting enzyme inhibition (ACEI) or chronic blockade of AT1 receptors (ARB). RESULTS: In rats, acute or chronic dDAVP infusion increased UAE significantly and reversibly (4-fold and 6-fold, respectively). In healthy subjects, acute infusion of dDAVP tripled UAE (P<0.01) but did not change creatinine and beta(2)-microglobulin excretion, thus suggesting that the rise in UAE was due to an increased glomerular leakage of albumin. dDAVP also increased UAE in patients with central DI and in patients with hereditary nephrogenic DI bearing AQP2 mutations. However, UAE was not increased in patients with hereditary nephrogenic DI bearing mutations of the V(2) receptor. In rats, ACEI and ARB blunted the dDAVP-induced rise in UAE by 70% (P<0.05) and 50% (NS), respectively. CONCLUSIONS: The present studies reveal for the first time that vasopressin induces a marked increase in UAE in healthy rats and humans. This albuminuric effect seems to result from increased glomerular leakage, requires functional vasopressin V(2) receptors, and is, at least in part, mediated by the renin-angiotensin system. These results bring additional support for an involvement of vasopressin in the albuminuria observed in pathological states such as diabetes mellitus or hypertension.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Vasopressin contributes to albuminuria and diabetes-induced nephropathy in animal models.
“Additionally, VP was shown to contribute to albuminuria and to diabetes-induced nephropathy in animal models [20,21].”
From Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats (2015) · cites this paper as [20]
Cites
Anderson, S., Rennke, H. G., & Brenner, B. M. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112528 · Cited by 1,066 · see citing works
Nephron adaptation to renal injury or ablation
Brenner, B. M. (1985) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1985.249.3.f324 · Cited by 643 · see citing works
Bichet, D. G., Razi, M., Lonergan, M., Arthus, M., Papukna, V., Kortas, C., & Barjon, J. N. (1988) · New England Journal of Medicine · doi:10.1056/nejm198804073181403 · Cited by 239 · see citing works
Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat
Bouby, N., Bachmann, S., Bichet, D. G., & Bankir, L. (1990) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1990.258.4.f973 · Cited by 182 · see citing works
Molecular Pharmacology of Human Vasopressin Receptors
Thibonnier, M., Conarty, D. M., Preston, J. A., Wilkins, P. L., Berti‐Mattera, L. N., & Mattera, R. (1998) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4871-3_34 · Cited by 145 · see citing works
Bardoux, P., Martin, H., Ahloulay, M., Schmitt, F., Bouby, N., Trinh-Trang-Tan, M.-M., & Bankir, L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10397 · Cited by 138 · see citing works
Self-citationTerada, Y., Tomita, K., Nonoguchi, H., Yang, T., & Marumo, F. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116838 · Cited by 135 · see citing works
Vasopressin increases glomerular filtration rate in conscious rats through its antidiuretic action.
Bouby, N., Ahloulay, M., Nsegbe, E., Déchaux, M., Schmitt, F., & Bankir, L. (1996) · Journal of the American Society of Nephrology · doi:10.1681/asn.v76842 · Cited by 116 · see citing works
Vasopressin and diabetes mellitus
Bankir, L., Bardoux, P., & Ahloulay, M. (2001) · Nephron · doi:10.1159/000045879 · Cited by 110 · see citing works
Self-citationAngiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney.
Łapiński, R., Perico, N., Remuzzi, A., et al. (1996) · Journal of the American Society of Nephrology · doi:10.1681/asn.v75653 · Cited by 110 · see citing works
Direct and indirect cost of urea excretion
Bankir, L., Bouby, N., Trinh‐Trang‐Tan, M., Ahloulay, M., & Promeneur, D. (1996) · Kidney International · doi:10.1038/ki.1996.232 · Cited by 88 · see citing works
Contribution of vasopressin to progression of chronic renal failure: Study in Brattleboro rats
Bouby, N., Hassler, C., & Bankir, L. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00330-6 · Cited by 78 · see citing works
Bankir, L., & Kriz, W. (1995) · Kidney International · doi:10.1038/ki.1995.2 · Cited by 72 · see citing works
Koga, M., Otsuki, M., Kubo, M., Hashimoto, J., & Kasayama, S. (1998) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199808)15:8 · Cited by 58 · see citing works
Costerousse, O., Allegrini, J., Clozel, J., et al. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37320-3 · Cited by 44 · see citing works
Sex differences in the endocrine predictors of essential hypertension. Vasopressin versus renin.
Cowley, A. W., Skelton, M. M., & Velasquez, M. T. (1985) · Hypertension · doi:10.1161/01.hyp.7.3_pt_2.i151 · Cited by 36 · see citing works
van Lieburg, A. F., Knoers, N. V. A. M., Monnens, L. A. H., & Smits, P. (1995) · Journal of Hypertension · doi:10.1097/00004872-199512010-00034 · Cited by 31 · see citing works
Association of arginine vasopressin and arterial blood pressure in a population-based sample
Zhang, X., Hense, H., Riegger, G. A. J., et al. (1999) · Journal of Hypertension · doi:10.1097/00004872-199917030-00003 · Cited by 31 · see citing works
Nishikawa, T., Omura, M., Iizuka, T., et al. (1996) · PubMed · Cited by 19 · see citing works
Effects of DDAVP on renal hemodynamics and renin secretion in subjects with essential hypertension.
Brink, H. S., Derkx, F. H. M., Boomsma, F., et al. (1994) · PubMed · Cited by 16 · see citing works
Desmopressin in Bleeding Disorders
Mariani, G., Mannucci, P. M., & Cattaneo, M. (1993) · Springer eBooks · doi:10.1007/978-1-4615-2922-4 · Cited by 14 · see citing works
Disparate expression of the AVP gene in Sabra hypertension-prone and hypertension-resistant rats
Yagil, C., Ben‐Ishay, D., & Yagil, Y. (1996) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1996.271.4.f806 · Cited by 13 · see citing works
The Hemodynamic and Coagulant Effects of DDAVP Are Specific Extrarenal V2- Receptor Responses
Bichet, D. G., Arthus, M., & Lonergan, M. (1993) · Springer eBooks · doi:10.1007/978-1-4615-2922-4_10 · Cited by 3 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Vasopressin: a novel target for the prevention and retardation of kidney disease?
Bankir, L., Bouby, N., & Ritz, E. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.22 · Cited by 214 · see citing works
Meijer, E., Bakker, S. J. L., Halbesma, N., de Jong, P. E., Struck, J., & Gansevoort, R. T. (2010) · Kidney International · doi:10.1038/ki.2009.397 · Cited by 123 · see citing works
Plasma Copeptin and Renal Outcomes in Patients With Type 2 Diabetes and Albuminuria
Velho, G., Bouby, N., Hadjadj, S., Matallah, N., Mohammedi, K., Fumeron, F., Potier, L., Bellili-Munoz, N., Taveau, C., Alhenc-Gelas, F., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0683 · Cited by 89 · see citing works
Taveau, C., Chollet, C., Waeckel, L., Desposito, D., Bichet, D. G., Arthus, M.-F., Magnan, C., Philippe, E., Paradis, V., Foufelle, F., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3496-9 · Cited by 86 · see citing works
- Authors
- Bardoux, P.
- Affiliations
- Inserm (FR)
- Corresponding author
- Bardoux, P.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-03-01
- Volume
- 18
- Issue
- 3
- Pages
- 497-506
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2120793874
- Cited by
- 136
- References
- 23
- Citations by year
- 2024: 7 · 2023: 6 · 2022: 5 · 2021: 6 · 2020: 7 · 2019: 11 · 2018: 9 · 2017: 12 · 2016: 8 · 2015: 10 · 2014: 9 · 2013: 7 · 2012: 3
- FWCI
- 1.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nephrology Dialysis Transplantation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Keywords
- urinary albumin excretion, albuminuria, V2 receptor, renin-angiotensin system, desmopressin, diabetes insipidus, nephrogenic diabetes insipidus, angiotensin-converting enzyme inhibition, AT1 receptor blockade, diabetes mellitus
- MeSH terms
- Adult, Albuminuria, Animals, Blood Pressure, Deamino Arginine Vasopressin, Diabetes Insipidus, Female, Humans, Male, Reference Values, Renal Agents, Renin-Angiotensin System, Vasopressins, Receptors, Vasopressin, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review